Product Description
MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695563/)
Mechanisms of Action: TFPI Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GC Biopharma Corp
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for MG-1113](https://pryzm-maps.s3.us-west-2.amazonaws.com/169current_maps.png)
Countries in Clinic: Korea
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Hemophilia A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MG1113_HP_P0101 | P1 |
Recruiting |
Hemophilia A |
2024-07-31 |
|
MG1113_P1 | P1 |
Completed |
Hemophilia A |
2021-06-30 |
21% |